Evidence map›Paper›PMID 40735804›Full record

ArticleDiabetes, obesity & metabolism2025

Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.

Chisom Kanu, Qiwei Wu, Jiat Ling Poon, Iris Goetz, Magaly Perez-Nieves, Kristina Boye, Corby K Martin, Tamer Coskun, Mark L Hartman

Abstract readLetter
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chisom KanuEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-2621-8652
Qiwei WuEli Lilly and Company, Indianapolis, Indiana, USA.
Jiat Ling PoonEli Lilly and Company, Indianapolis, Indiana, USA.
Iris GoetzEli Lilly and Company, Indianapolis, Indiana, USA.
Magaly Perez-NievesEli Lilly and Company, Indianapolis, Indiana, USA.
Kristina BoyeEli Lilly and Company, Indianapolis, Indiana, USA.
Corby K MartinIngestive Behavior, Weight Management & Health Promotion Laboratory, Human Phenotyping Core, Nutrition Obesity Research Center, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA.ORCID https://orcid.org/0000-0002-8125-4015
Tamer CoskunEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-2481-133X
Mark L HartmanEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Sujoy Ghosh · 2005 to 2026
$26.5M
Eli Lilly and CompanyNational Institute of General Medical Sciences, which funds the Louisiana Clinical and Translational Science Center U54GM104940NIDDK NIH HHS P30 DK072476NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti‐obesity drugappetite controlpatient‐reported outcomesweight management

Identifiers

PMID40735804
PMCPMC12409224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.